126 related articles for article (PubMed ID: 9286047)
1. Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long-lasting humoral and cellular responses in adults.
Di Tommaso A; Bartalini M; Peppoloni S; Podda A; Rappuoli R; De Magistris MT
Vaccine; 1997 Aug; 15(11):1218-24. PubMed ID: 9286047
[TBL] [Abstract][Full Text] [Related]
2. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.
Leroux-Roels G; Lattanzi M; Solis CD; Contorni M; Costantini M; Moraschini L; Bardelli M; Bertholet S; Borgogni E; Buricchi F; Cantisani R; Faenzi E; Finco O; Leuzzi R; Pizza M; Rosa D; Schiavetti F; Seubert A; Spensieri F; Volpini G; Zedda L; Giudice GD; Galgani I
Hum Vaccin Immunother; 2018 Jan; 14(1):45-58. PubMed ID: 29172945
[TBL] [Abstract][Full Text] [Related]
3. Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age.
Huang LM; Lee CY; Lin TY; Chen JM; Lee PI; Hsu CY
Vaccine; 1996 Jun; 14(9):916-22. PubMed ID: 8843635
[TBL] [Abstract][Full Text] [Related]
4. Specific immune response in adult medical personnel immunized with acellular pertussis vaccine with special emphasis on T helper cell response.
Lin TY; Chiang BL
Vaccine; 1997 Dec; 15(17-18):1917-21. PubMed ID: 9413102
[TBL] [Abstract][Full Text] [Related]
5. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
[TBL] [Abstract][Full Text] [Related]
6. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
[TBL] [Abstract][Full Text] [Related]
7. Acellular and whole cell pertussis vaccines protect against the lethal effects of intracerebral challenge by two different T-cell dependent humoral routes.
Wiertz EJ; Walvoort HC; Van Loveren H; Van Straaten-Van De Kappelle I; Van Der Gun JW; Kreeftenberg JG
Biologicals; 1990 Jul; 18(3):173-80. PubMed ID: 2257130
[TBL] [Abstract][Full Text] [Related]
8. An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Pennridge Pediatric Associates.
Rothstein EP; Anderson EL; Decker MD; Poland GA; Reisinger KS; Blatter MM; Jacobson RM; Mink CA; Gennevois D; Izu AE; Sinangil F; Langenberg AG
Vaccine; 1999 Aug; 17(23-24):2999-3006. PubMed ID: 10462235
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.
Podda A; Carapella De Luca E; Titone L; Casadei AM; Cascio A; Bartalini M; Volpini G; Peppoloni S; Marsili I; Nencioni L
J Pediatr; 1993 Jul; 123(1):81-4. PubMed ID: 8320630
[TBL] [Abstract][Full Text] [Related]
10. Antibody responses after vaccination and disease against leukocytosis promoting factor, filamentous hemagglutinin, lipopolysaccharide and a protein binding to complement-fixing antibodies induced during whooping cough.
Winsnes R; Lønnes T; Møgster B; Berdal BP
Dev Biol Stand; 1985; 61():353-65. PubMed ID: 2872124
[TBL] [Abstract][Full Text] [Related]
11. Long-term immunogenicity of a single dose of acellular pertussis vaccine in paediatric health-care workers.
Littmann M; Hülsse C; Riffelmann M; Wirsing von König CH
Vaccine; 2008 May; 26(19):2344-9. PubMed ID: 18396360
[TBL] [Abstract][Full Text] [Related]
12. Engineering bacterial toxin for the development of new vaccine against pertussis.
Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of a three-component acellular pertussis vaccine administered at birth.
Belloni C; De Silvestri A; Tinelli C; Avanzini MA; Marconi M; Strano F; Rondini G; Chirico G
Pediatrics; 2003 May; 111(5 Pt 1):1042-5. PubMed ID: 12728086
[TBL] [Abstract][Full Text] [Related]
15. The cell mediated and humoral immune response to vaccination with acellular and whole cell pertussis vaccine in adult humans.
Petersen JW; Ibsen PH; Bentzon MW; Capiau C; Heron I
FEMS Microbiol Immunol; 1991 Oct; 3(5):279-87. PubMed ID: 1797049
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa.
Podda A; Nencioni L; Marsili I; Peppoloni S; Volpini G; Donati D; Di Tommaso A; De Magistris MT; Rappuoli R
Vaccine; 1991 Oct; 9(10):741-5. PubMed ID: 1759492
[TBL] [Abstract][Full Text] [Related]
17. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses.
Cherry JD; Gornbein J; Heininger U; Stehr K
Vaccine; 1998 Dec; 16(20):1901-6. PubMed ID: 9796041
[TBL] [Abstract][Full Text] [Related]
18. Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine.
Thomas MG; Ashworth LA; Miller E; Lambert HP
J Infect Dis; 1989 Nov; 160(5):838-45. PubMed ID: 2572651
[TBL] [Abstract][Full Text] [Related]
19. Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial.
Pitisuttithum P; Chokephaibulkit K; Sirivichayakul C; Sricharoenchai S; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chauhan M; Wijagkanalan W; Hommalai G; Fortuna L; Chinwangso P; Poredi IK; van den Biggelaar AHJ; Pham HT; Viviani S
Lancet Infect Dis; 2018 Nov; 18(11):1260-1268. PubMed ID: 30266329
[TBL] [Abstract][Full Text] [Related]
20. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]